Funder: European Hematology Association; Id: http://dx.doi.org/10.13039/100008594Funder: La Ligue contre le cancer; Id: http://dx.doi.org/10.13039/501100004099Funder: Wellcome Trust; Id: http://dx.doi.org/10.13039/100004440Funder: Association Laurette Fugain; Id: http://dx.doi.org/10.13039/100007394Funder: Biotechnology and Biological Sciences Research Council; Id: http://dx.doi.org/10.13039/501100000268Funder: Assistance Publique ‐ Hôpitaux de Paris; Id: http://dx.doi.org/10.13039/501100002738Funder: Medical Research Council; Id: http://dx.doi.org/10.13039/501100000265Funder: Institut National Du Cancer; Id: http://dx.doi.org/10.13039/501100006364It is essential to relate the biology of acute leukaemia to normal blood cell development. In this review, we discuss how modern models of haematopoiesis might inform approaches to diagnosis and management of immature leukaemias, with a specific focus on T‐lymphoid and myeloid cases. In particular, we consider whether next‐generation analytical tools could provide new perspectives that could improve our understanding of immature blood cancer biology
